Background-Pericytes represent a unique subtype of microvessel-residing perivascular cells with diverse angiogenic functions and multilineage developmental features of mesenchymal stem cells. Although various protocols for derivation of endothelial and/or smooth muscle cells from human pluripotent stem cells (hPSC, either embryonic or induced) have been described, the emergence of pericytes in the course of hPSC maturation has not yet been elucidated. Methods and Results-We found that during hPSC development, spontaneously differentiating embryoid bodies give rise to CD105 ϩ CD90 ϩ CD73 ϩ CD31 Ϫ multipotent clonogenic mesodermal precursors, which can be isolated and efficiently expanded. Isolated and propagated cells expressed characteristic pericytic markers, including CD146, NG2, and platelet-derived growth factor receptor ␤, but not the smooth muscle cell marker ␣-smooth muscle actin. Coimplantation of hPSC-derived endothelial cells with pericytes resulted in functional and rapid anastomosis to the murine vasculature. Administration of pericytes into immunodeficient mice with limb ischemia promoted significant vascular and muscle regeneration. At day 21 after transplantation, recruited hPSC pericytes were found incorporated into recovered muscle and vasculature.
I n adult tissues, the majority of blood vessels are composed of 3 layers including a luminal inner monolayer of endothelial cells (EC), tunica intimae, an intermediate muscular layer, tunica media, of smooth muscle cells (SMC) and an outer layer of fibroblast-like adventitial cells and connective tissue components, tunica adventitia. Microvessels, including capillaries, precapillary arterioles, postcapillary venues, and collecting venules are composed of internal endothelial layer surrounded by outer coverage of pericytes (also known as Rouget cells or mural cells). 1 Both perivascular SMC and pericytes have been shown to function as critical regulators of vascular development, stabilization, maturation, and remodeling mediated by transforming growth factor ␤ (TGF-␤), platelet-derived growth factor B, or angiopoietin-1. 2, 3 Although related in function and anatomic localization, pericytes can be distinguished from SMC on the basis of their characteristic morphology and specific cell marker expression: Whereas SMC form a separate layer of the tunica media in blood vessels, pericytes are physically embedded within the endothelial basement membrane to promote mutual communication with the underlying endothelium. 4 In addition, SMC and the majority of pericytes in multiple human and murine tissue types express ␣-smooth muscle actin (␣-SMA), which is involved in regulation of vessel contractility. 5 Although specific markers of pericytes are not defined yet, the majority coexpress ␣-SMA, CD133, NG2, CD146, alkaline phosphatase and platelet-derived growth factor receptor ␤ (PDGFR-␤), with minor subsets coexpressing CD34 6 or do not express ␣-SMA 7 and minor subsets of pericytes assumed to represent more primitive pericytic precursors.
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Besides possessing angiogenic features, subsets of blood vessel-residing cells are defined as stem cells, which are capable of multiple developmental paths, including osteogenic, chondrogenic, adipogenic, and myogenic differentia-tion. 5, 6 During early stages of vertebrate embryogenesis, and similarly in embryonic stem cell differentiation, EC arise from mesodermal angioblast/hemangioblast precursors. 8 -10 In comparison, the ontogeny of pericytes is more complex, shares similarities with SMC, and is related to their deposition in different regions of the body. 11 In adult tissue, the saphenous vein was shown to contain a novel subset of CD34 ϩ CD31 Ϫ pericytic precursors. 6 In vitro, the pluripotent differentiation capability of human embryonic stem cells (hESC), 12 and more recently the rapidly growing platform of human-induced pluripotent stem cells (hIPSC), 13 provides a powerful model system to study vasculogenic development. Several studies have described protocols for the derivation of endothelial and SMC from progenitor cells. 14 -17 However, derivation of multipotent vasculogenic pericyte population from hPSC was not documented until now. Therefore, we used differentiating hPSC as a model to determine whether pericytes emerge alongside with development of endothelial and SMC on the basis of common (CD105, ␣-SMA) and specific (CD31, vascular endothelial cadherin, europaeus agglutinin-1 [UEA-1]) vascular cell markers. We have identified a novel population of cells, positive for recognized markers of pericytes, including NG2, PDGFR-␤, and CD146, but not ␣-SMA and characteristic markers of mesenchymal stem cells (MSC). Herein we describe a protocol for coisolation of vasculogenic derivatives from a single source of hPSC, including pericytes, SMC, and EC. In addition, we identify the conditions for long-term cultivation of clonogenic hPSC pericytes, which steadily maintained perivascular and multilineage characteristics in vitro and in vivo and were proved useful in the treatment of severely ischemic tissue.
Methods
An expanded online-only Data Supplement Methods section is available in the online-only Data Supplement.
Pericyte and Endothelial Progenitor Cell Isolation
At indicated time points of spontaneous differentiation in embryoid bodies (EBs), single-cell suspensions were made from differentiated hPSC, including human ESC H9.2 18 and I6, 19 hIPSC human foreskin fibroblast-derived C3, 20 and human hair follicle keratinocyte-derived KTR13. 21 CD31 ϩ EC or CD105 ϩ cells were isolated from differentiated hPSC using MACS MicroBeads (Miltenyi Biotec) according to the manufacturer's instructions. As determined by flow cytometry, the purity of isolated CD31 ϩ or CD105 ϩ cells was generally 60% to 70% at a single column, and Ͼ96% after the second column. Dissociated EB-derived CD105 ϩ CD31 ϩ or CD105 ϩ CD31 Ϫ subpopulations were isolated by fluorescence-activated cell sorting (Becton Dickinson Immunocytometry Systems). In some experiments, CD31 ϩ EC were isolated from cultured hPSCderived CD105 ϩ cells for further expansion (purity of CD31 ϩ Ͼ97%) of either CD105 ϩ CD31 ϩ EC or CD105 ϩ CD31 Ϫ pericytes.
Matrigel Implants
Endothelial cells (human umbilical vein EC [HUVEC] or hPSCderived EC) or hPSC pericytes were resuspended in 250 L phenol-red free Matrigel (BD Biosciences), either alone (3-5ϫ10 5 EC, 6 -8ϫ10 5 pericytes) or mixed (1:1). Matrigel mixture was then injected subcutaneously into 6-to 8-week-old nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Implants were removed at the indicated time points, fixed in 4% formalin, sectioned, and stained with Hematoxylin/Eosin.
Hind Limb Ischemia Model
Male 8-week-old CD1 nude mice were subjected to hind limb ischemia by femoral artery ligation and transection. After surgery, mice received of 2ϫ10 6 hPSC pericytes (H9.2, I6, or C3) or unconditioned M-199 medium (200 L) intramuscularly into 4 sites of the gracilis muscle in the medial thigh. Limb perfusion was assessed with a noncontact laser Doppler at days 0, 7, 14, and 21 after treatment.
Statistical Analyses
A t test was used for comparisons between 2 groups (analyses were performed with Excel 2007). Repeated measures ANOVA (analyses were performed with IBM SPSS statistic 19) was used for analyses of blood flow recovery, in which measurements were repeated for the same subject at the same time point (PϽ0.05 was inferred to denote statistical significance) and followed by Bonferroni post hoc test.
Results

Emergence of Vasculogenic Progenitor Cells in Developing EBs
The emergence of vasculogenic populations from hPSC was examined in spontaneously differentiating EBs. For characterization of vasculogenic precursors, developing EBs were analyzed for the expression of CD105 and CD73, which have been reported to be expressed on both endothelial and mural cells in blood vessels. 5 Quantitative polymerase chain reaction (PCR) analyses of differentiating EBs demonstrated that CD105 and CD73 expression was detected between days 4 and 26 in culture, upregulated between days 10 and 14, and decreased between days 19 and 26 ( Figure 1A ). The expression of the EC marker vascular endothelial cadherin was increased during 14 days of differentiation with low to undetectable expression thereafter ( Figure 1A ). Flow cytometry analyses for the expression of an additional EC marker CD31 with CD105 revealed that 2 distinguished cell subsets contributed to the overall increase in CD105 messenger RNA expression as follows: Until day 14 the majority of CD105 ϩ cells were composed of CD105 ϩ CD31 ϩ EC with a small subset of nonendothelial CD105 ϩ CD31 Ϫ population ( Figure  1B ). From day 19 onward the percentage of CD105 ϩ CD31 ϩ EC as well as CD31 messenger RNA expression declined progressively coinciding with an increase in the percentage of CD105 ϩ CD31 Ϫ or CD73 ϩ CD31 Ϫ nonendothelial subsets ( Figure 1B-1D ). Of note: In comparison to published data, 22 our optimized dissociation protocol of EBs and cell isolation significantly increased (from 1%-1.5% to 3%-7% CD31 ϩ cells) the apparent percentage of dissociated CD105 ϩ CD31 ϩ cells (H9.2 nϭ30, I6 nϭ8, and C3 nϭ12,) and significantly increased the yield of isolated cells with 95% cell viability ( Figure 1B and Figure I in the online-only Data Supplement). These results ( Figure 1C and 1D) support the emergence of a CD105 ϩ and/or CD73 ϩ CD31 Ϫ nonendothelial mural subsets during the onset of vasculogenesis in hPSC-derived EBs. Therefore, 14-day-old dissociated EBs were analyzed by flow cytometry using triple labeling with antibodies against CD105 and CD31 with either CD146 or CD73 (Figure 2A ). Within CD105 ϩ CD31 Ϫ populations, Ϸ25% coexpressed CD146 and 22% CD73 (Figure 2A ), which are also expressed by perivascular cells of blood vessels. 5 In addition, CD90 ϩ CD31 Ϫ clusters were observed in 17-day-old EBs, with CD90 ϩ CD31 Ϫ in proximity and aligning the CD31 ϩ vascular network ( Figure 2B ). The majority of CD90 ϩ cells coexpressed calponin, which is another characteristic marker of perivascular cells ( Figure 2C and Movie I in the onlineonly Data Supplement). Of note, CD73 and CD105 are expressed also by subsets of blood-derived CD45 ϩ hematopoietic cells. However, it is well established that in the course of the spontaneous differentiation of EBs only very rare events (Ͻ0.02%) of CD45 ϩ hematopoietic mature cells are detected 10 ( Figure II in the online-only Data Supplement), and the induction of differentiation of hematopoietic lineages requires further maturation of CD34 ϩ /angiotensin-converting enzyme-positive progenitor cells on specific cell feeders. 10, 23 Altogether, these results demonstrate that a subset of nonendothelial/nonhematopoietic CD105 ϩ CD31 Ϫ spontaneously emerge in the course of vasculogenesis in differentiating hPSC and may represent a perivascular progenitor cell population with potential vasculogenic properties.
Characterization of Pericyte-Like Progenitor Cells
Next, CD105 ϩ cells were isolated from 13-to 19-day-old EBs for further cultivation. Within 1 to 2 passages, the CD105 ϩ CD31 Ϫ subset dominated the mixed CD105 ϩ vasculogenic cultures ( Figure III in the online-only Data Supplement), exhibiting loosened cell-cell contacts in a multilayered hill-and-valley morphology 24 ( Figure III in the online-only Data Supplement), which is typical of cultured pericytes as well as SMC. Both hESC and hIPSC pericytes exhibited similar growth potential in long-term cultures up to 8 passages for 8 weeks, with a population doubling time of 108 hours between weeks 1 and 2 and a faster growth rate between weeks 3 and 5, at which point the population doubling time was Ϸ60 hours. After 7 weeks of culture, pericytes gradually entered hypertrophic senescence ( Figure  2D ). Contact inhibition was not observable and adherent spherical clusters of multilayered cells were detached from the plastic at high densities (data not shown). CD105 ϩ CD31 Ϫ pericyte-like cells could be efficiently expanded: up to 2900-, 5000-, and 4200-fold increase for H9.2, I6, and C3, respectively ( Figure 2E ). To examine their clonogenic potential, sorted CD105 ϩ CD31 Ϫ cells were cultured, prelabeled with the CellTracker CM-DiI ( Figure 2F ), cloned (passages 2-4) by limiting dilution in Terasaki plates, and scored 24 hours post seeding for the efficiency of single-cell seeding ( Figure  2F and 2G). One week later, 16.5Ϯ1.1% of H9.2, 18.5Ϯ2.7% of I6, and 16.8Ϯ2.7% of C3 single-adhesive pericyte-formed colonies ( Figure 2H ) with similar pericytic morphology ( Figure 2F ). Long-term cultured pericytes exhibited a uniform and high expression of a comprehensive set of markers characteristic of perivascular and MSC, including maintenance of CD105 expression in long-term culture, as well as CD73, CD29, CD44, CD90, and CD146 ( Figure 3A ). From the first passage to senescence, the majority of pericytes were negative for ␣-SMA, with only 6% to 8.5% ␣-SMA ϩ cells throughout the culture period ( Figure 3B ). Similar to adultderived pericytes and MSC, isolated and cultured CD105 ϩ CD31 Ϫ cells did not express CD56 and endothelial cadherin or specific markers of endothelial (CD34, CD31, von Willebrand factor, vascular endothelial cadherin), or hematopoietic (CD45, CD14) cells ( Figure 3A and data not shown). In addition, PCR analyses of sorted CD105 ϩ CD31 Ϫ and CD105 ϩ CD31 ϩ subpopulations, endogenous placentaderived pericytes, and hPSC vascular derivatives at early and late passages demonstrated coexpression of markers indicative of perivascular/MSC phenotype in isolated and cultured CD105 ϩ CD31 Ϫ cells, with CD31 expression only in endothelial hPSC derivatives ( Figure 3C ). In accordance with their perivascular cell-like appearance and in a fashion similar to that of human placenta CD146 ϩ CD31 Ϫ pericytes, hPSC pericytes were immunolabeled for recognized pericytic markers including NG2, PDGFR-␤, calponin, and nestin ( Figure  3D ). Furthermore, cultivated pericytes expressed Tei-2 (Figure 3D-X and 3D-XI) and fibroblast-specific protein 1 (Figure 3D -XII), which is expressed by myofibroblasts and cardiac mesenchymal derivatives of transdifferentiating EC. 25, 26 
CD105 ؉ CD31 ؊ hPSC Pericytes and EC Assemble to Generate Human Vascular Network
The vasculogenic potential of the pericytes was initially evaluated in vitro. Although tube formation on Matrigel is a common feature of EC, it has been previously demonstrated that fetal tissue pericytes can actively create tubular networks. 27 In accordance with this finding, hPSC pericytes formed short intricate tubular structures on Matrigel within 2 hours ( Figure 4A ) whereas HUVEC (data not shown) or hPSC-derived CD31 ϩ EC rearranged into linear asymmetrical tube networks ( Figure 4A ). When CFSE-labeled pericytes were cocultured with H9.2 hESC CD31 ϩ EC on Matrigel, both cell types were assembled to form thicker tubular networks ( Figure 4B ). It has been previously demonstrated that the presence of murine or human adult tissue-derived mesenchymal precursors is essential for de novo generation and stabilization of vascular networks using immunodeficient murine experimental models. 14, 28, 29 Therefore, the vasculogenic potential of CD105 ϩ CD31 Ϫ pericytes was studied in vivo by the Matrigel implant assay. Pericytes and EC, either HUVEC or hPSC EC, were mixed in Matrigel and injected subcutaneously into immunodeficient NOD/SCID mice. In accordance with previous studies, 30 Hematoxylin/Eosin staining revealed that empty control Matrigel implants ( Figure  4C -I), implants with HUVEC (data not shown), or hPSC-CD31 ϩ cells only ( Figure 4C -II) did not contain microvessels. Implants with only pericytes induced some infiltration of murine vessels ( Figure 4C Figure 4D ). Of note, efficient generation of chimeric human vasculogenic structures was detected even when the implants were devoid of administration of angiogenic factors such as vascular endothelial growth factor (VEGF) and/or basic fibroblast growth factor. In addition, implantation within Matrigel induced ␣-SMA expression by implanted pericytes, demonstrating their ability to further differentiate in vivo toward SMC-like perivascular cells and implying for their more their immature phenotype in culture as SMC precursors ( Figure 4F ). Altogether, these findings support the notion that pericytes and SMC share a common progenitor, as was previously demonstrated using quail-to-chick transplantation 11 and mouse experimental models. 31 The ability of pericytes to recruit murine blood vessels and to support the formation as well as stabilization of the newly formed vascular network can be attributed in part to the secretion of VEGF, which is a key regulator of angiogenesis and vasculogenesis, as well as of EC survival. 32 In conformity with this suggestion, secreted VEGF 165 was detected by ELISA in the conditioned medium of cultivated pericytes ( Figure 4G ).
Durability of hPSC Pericyte-Based Vasculature
To further evaluate the engineered vasculature, luciferaselabeled hPSC pericytes were implanted in the presence or absence of HUVEC in Matrigel implants. Perfusion of the implants was then monitored at days 1, 7, and 14 using a luciferase-based live imaging system. Whereas strong bioluminescence signal was detected in all implants at day 1 ( Figure 5A ), pericytes survived up to 14 days postimplanta- tion only in implants in which HUVEC were coimplanted ( Figure 5A ). Matched histological data ( Figure 5B ) confirmed that the survival of luciferase ϩ pericyte in vivo correlated with significant and durable perfusion of the implants by de novo formation of human blood vessels ( Figure 5B ), which were stabilized by implanted pericytes. It appears that pericytes undergo a process of remodeling characterized by reduction in total cellularity and viability of the pericytes, which are not incorporated into engineered blood vessels. In addition, functionality of CM-DiI prelabeled hESC I6 vascular derivatives ( Figure 5C ) in Matrigel implants and anastomosis with murine circulation was examined after 7 days by intravenous administration of the humanspecific EC-binding lectin UEA-1 fluorescein isothiocyanate (FITC; Figure 5D ), which was incorporated into the human blood vessels ( Figure 5E ). Confocal microscopy slicing through blood vessel structures revealed nestin ϩ pericytes ( Figure 5F ) partially aligning CM-DiI ϩ (Figure 5G ) UEA-1 FITC ϩ ( Figure 5H and 5I and Movie II in the online-only Data Supplement) hPSC EC. Altogether, these results demonstrate that hPSC pericytes are crucial for rapid perfusion of the implants via a progressive process of vascular remodeling.
Human hPSC Pericytes Are Multipotent Clonogenic MSC
A perivascular origin for MSC was previously demonstrated in multiple human organs, which harbor a reserve of multipotent progenitor cells. 5 This notion, together with the expression of recognized MSC markers (Figure 3 ) and the vasculogenic functionality of hPSC pericytes (Figures 4 and  5 ) imply that these cells might have a developmental potential equivalent to MSC. Therefore, cultured pericytes were analyzed for their ability to form mesenchymal tissues, including bone, fat, cartilage, and muscle. On appropriate inductive experimental conditions, hPSC-pericytes (H9.2 and C3) exhibited uniform and efficient osteogenic appearance, with robust mineral and calcium depositions ( Figure 6A and 6B ). After short (3 days) or long (14 days) osteogenic stimulation in vitro, differentiated pericytes were subcutaneously implanted within Matrigel into NOD/SCID mice for assessment of ectopic bone formation. Examination of the implants 2 weeks later by staining for Hematoxylin/Eosin or Alizarin red revealed the presence of mineral deposits produced by 3 daysstimulated hIPSC pericytes ( Figure 6C and 6D) with a dramatic increase in mineral deposit content in implants of 14 days-stimulated pericytes ( Figure 6E and 6F ). In addition, more mature bone-like structures and erythrocyte-containing blood vessels could be seen in implants of 14 days-stimulated pericytes ( Figure 6E ). Furthermore, pericytes were capable of adipogenic ( Figure 6G and 6H) and chondrogenic ( Figure 6I and 6J) differentiation in vitro. High-efficiency (Ͼ95%) adipogenic differentiation and whole-cell osteogenic differentiation ( Figure VI in the online-only Data Supplement) were documented from passage 1 to passage 8 until senescence, designating that our culture conditions were sufficient for stabilization and maintenance of the multilineage features of expanded hPSC-CD105 ϩ /CD73 ϩ CD31 Ϫ pericytic precursors. After myogenic induction in vitro, skeletal myotubes could be detected ( Figure 6K and 6L and Figure VII in the online-only Data Supplement), with the fraction of differentiated hPSC pericytes expressing characteristic skeletal markers similar to that expressed by human-derived skeletal muscle ( Figure 6K and 6M) . Expandable single-cell-derived clones ( Figure 6N ) were further subdivided to give rise to tripotent osteogenic-chondrogenic-adipogenic pericytes (Figure 6O) , of which 16Ϯ0.5, 14Ϯ0.5, and 11Ϯ3 of H9.2, I6, and C3, respectively, exhibited myogenic differentiation ( Figure 6N and 6O ).
Transplantation of hPSC Pericytes Promotes Vascular and Muscle Recovery in Ischemic Limbs of Transplanted Mice
To determine the effectiveness of hPSC pericytes on vascular and muscle recovery, 2ϫ10 6 hPSC pericytes (H9.2, I6, and C3) or unconditioned medium were injected intramuscularly into the ischemic hind limb of immunodeficient CD1 nude mice. Representative laser Doppler perfusion images are shown weekly to document the recovery of perfusion ( Figure  7A ). Within 21 days, untreated control mice showed Ϸ2-fold endogenous recovery ( Figure 7B ), which was sufficient to prevent untoward morbidity or limb loss. In comparison, a significantly higher (Ϸ4-fold) and accelerated recovery of foot perfusion was measured in the pericyte-treated group ( Figure 7B and Figure VIII in the online-only Data Supplement). Histology of ischemic, nonischemic, and healthy muscle from mice that were not subjected to limb ischemia demonstrated that perfused blood vessel density was significantly (PϽ0.001) higher in pericyte-treated ischemic mice compared with the control group and compared with healthy muscle ( Figure 7C and Figure VIII in the online-only Data Supplement). At day 21 postinjection, CM-DiI-labeled pericytes were still detected incorporated into recovered muscle in ischemic limb but not in nonischemic or untreated ischemic limb ( Figure 7D ). Increased positive immunostaining for desmin revealed that muscle regeneration was more pronounced in the hPSC pericyte-treated group compared with the control group ( Figure 7D and 7E ). In addition, double staining of CM-DiI ϩ desmin ϩ of myotube-incorporated pericytes demonstrate their ability to contribute to myogenesis via direct myogenic differentiation ( Figure 7F ). Recruited CM-DiI ϩ pericytes maintained their perivascular features in ischemic tissues and were also found incorporated into murine blood vessels ( Figure 7G) . These data confirm that transplanted hPSC pericytes directly incorporate into host ischemic muscle and recovered vasculature to promote improvement in perfusion and muscle recovery.
Discussion
We have demonstrated that pericytic progenitor cells can be isolated from hPSC, including hESC and hIPSC, to be further efficiently expanded in long-term cultures, maintaining stable perivascular features and multilineage potential. Our protocol is based on 3-dimensional scalable (either hESC 33 or EBs 34 ) feeder-free differentiation platforms. In addition, we show that coimplantation of a single source-derived EC and pericytic progenitor cells in Matrigel into immunodeficient mice resulted in rapid formation of a robust vascular network, which anatomized the host circulation. Pericytes, immediately adjacent to the vascular endothelium of both arteries and veins, are not in themselves SMC. They do, however, share angiogenic properties and properties related to regulation of blood vessels. 3, 35 Similarly, we have demonstrated here that hPSC pericytes were found to reside around engineered blood vessels and were essential for the de novo formation of these .0005 compared with Day 0) and in density of perfused blood vessels at day 21 (C, *PϽ0.05 and **PϽ0.001 compared with treated mice; #PϽ0.001 compared with nonischemic mice) was measured for all hPSC pericyte-treated mice compared with control mice. Data are meanϮSEM. D through G, Human pluripotent stem cell pericytes are recruited to the recovered ischemic muscle. Representative images of myogenesis evaluated with desmin stain (green, D through F) at day 21 in either control ischemic muscle (D, low expression) and ischemic muscle treated with CM-DiI (red, E through G) labeled hPSC pericytes (E and F, high expression), which are seen incorporated into recovered myofibers. G, CM-DiI-labeled pericytes (red) aligning (arrowheads and inset) von Willebrand factor ϩ (green) EC of perfused blood vessel or incorporated into the ischemic muscle. Nuclear staining by DAPI (blue). iPSC indicates induced pluripotent stem cells; hESC, human embryonic stem cells; and PSC, pluripotent stem cells. blood vessels. These findings are consistent with previous reports showing that interactions between EC and murine perivascular cells are essential for development of vascular networks in vivo. In previous models, either murine embryonic cell line 10T1/2 14, 36 or murine myofibroblasts 22 were used as perivascular cells. However, neither source is useful for clinical applications. Although protocols for generation of perivascular hESC-derived SMC, with therapeutic effectiveness in limb and cardiac ischemic experimental models were previously described, 9, 22, 37 it is not clear whether sufficient numbers of SMC with stable phenotype can be achieved in long-term culture as a fundamental need for potential usage in regenerative medicine. In addition, generation of mature functional SMC on murine OP9 feeder, in a 2-dimensional (2D) differentiation system, was previously described. 15 However, it is not clear whether OP9-induced differentiation results in generation of multipotent pericyte-like perivascular cells or directly induces the production of terminally differentiated SMC via another mechanism of cell commitment. Furthermore, OP9 feeder also induces the differentiation of hematopoietic CD105 ϩ CD45 ϩ or CD73 ϩ CD45 ϩ from hPSC-derived progenitor cells, 23, 38 making this and similar 2D differentiation protocols unsuitable for our CD105/CD73based isolation approach.
In our cultures, pericytes were rapidly and robustly expanded and could further gain SMC phenotype in vivo when implanted together with EC in Matrigel while uniformly maintaining multilineage potential throughout the whole culture period. Similarly, human bone marrow-derived adult MSC gained mature SMC phenotype when implanted with cord blood-derived EC and could be efficiently expanded. 30 However, the differentiation potential of expanded MSC is significantly reduced with increasing cell passages and is donor-age restricted 39 because of heterogeneous deterministic hierarchy 40 and acquired in vitro cues in long-term cultures. Protocols for induction of differentiation in serum-free cultures and sequential activation by various growth factors enable the generation of either mesodermal progenitor cells 41 or EC. 17 Further studies are required to evaluate whether culture conditions, in particular differentiation in 2D-induced and defined cultures, which favors the emergence and stabilization of particular derivatives that affect the specification of pericytes in developing hPSC. For example, although blockade of TGF-␤ signaling at initial developmental stages of hPSC induce neural conversion, 42 inhibition of TGF-␤ signaling after specification of mesodermal progenitor cells contributes to generation of EC. 17 However, TGF-␤ signaling interferes with the maturation as well as stabilization of vascular phenotypes of hPSC endothelial progenitor cells and was shown to be involved in cell differentiation toward ␣-SMApositive SMC. 36, 43 Interestingly, CD34 ϩ NG2 ϩ PDGFR-␤ ϩ CD31 Ϫ perivascular progenitor cells were detected in human saphenous veins. After isolation, CD34 ϩ cells differentiated in vitro into multipotent pericytes while losing CD34 expression. 6 These findings coincide with an alternative pathway for derivation of perivascular EC or SMC from hESC, in which CD34 ϩ progenitor cells are further induced to differentiate into these vascular derivatives. 22, 44 Saphenous vein-derived CD34 ϩ cells may therefore represent progenitor intermedi-ates of differentiating CD34 ϩ during induced commitment toward the perivascular lineage in native tissue and in the course of hESC differentiation. In view of the fact that implantation of either HUVEC, blood-derived EC, 30 or-as demonstrated here-hPSC-derived EC is insufficient for the formation of vascular network in the absence of supporting perivascular cells, the effort to achieve large numbers of EC from hPSC should be accompanied by the ability to gain sufficient numbers of perivascular cells, including SMC or pericytes.
Previous attempts to generate perivascular cells from hESC resulted in the generation of ␣-SMA-positive SMC. 9, 14, 17, 22, 37 Intact SMC can be distinguished from pericytes in fetal or adult tissues on the basis of a combination of cell markers, cell morphology, and the size of the blood vessels in their tissue of origin. However, in differentiating hPSC, visualization of pericytes cannot be based on correlation between their anatomic localization in physiological association with vascular endothelium together with expression of a combination of cell markers (eg, CD146, NG2, CD90) and the absence of others (eg, CD31, CD56) 5 because of nonorganized immature vascular appearance in developing hPSC. 9 In addition, MSC and pericytes share the common features of multilineage progenitors 7 but exhibit distinct characteristics, as well. Therefore, a comprehensive set of pericytic markers, morphology in culture, and perivascular and MSC features should be demonstrated in order to define the hPSC pericyte equivalents. Generation of MSC from hESC was previously demonstrated using 2 distinguished protocols involving either neural crest progenitor cell CD73 ϩ progeny 45 or CD73 ϩ mesoendodermal precursors, 46 with the neural crest progenitor-derived CD73 ϩ precursors differing from the mesodermal intermediates in their inability to give rise to skeletal muscle progeny. 45, 46 However, several reports demonstrate that cranial and cephalic neural crests give rise to pericytes and smooth and skeletal muscle cells in vivo. 31, 47 We report here that hPSC pericytes exhibited myogenic differentiation in vitro and in vivo as well as characteristic perivascular morphology in cultures, with hill-and-valley morphology and no contact inhibition. In addition, the lack of ␣-SMA expression distinguishes the hPSC pericytes from the ␣-SMApositive mesodermal progenitor cells, which were derived by different protocols, 46, 48 and suggest that these intermediates represent more primitive perivascular precursors, with MSCdefinitive characteristics. In addition, the type and the time course of emergence of hPSC-cell intermediates are largely dependent on the dynamic or induced environmental cues. For example, paraxial mesodermal-derived CD73 ϩ MSC were generated by long-term differentiation of hESC in 2D culture 46 wherein alternative protocol and experimental conditions were used to generate CD73 ϩ MSC, this time from isolated neural crest progenitor cells. 45 Furthermore, in the course of vertebrate valvulogenesis in the developing heart, endocardial cells undergo endothelial to mesenchymal transition in a VEGF-, Notch-, and TGF-␤dependent manner. 49 The nuclear factor of activated T cells-positive endocardial subset was also identified in differentiating murine EBs, 50 implying that endothelial intermediates in differentiating hPSC can serve as an alternative source for pericytes.
Supporting this notion, transcripts and protein expression of the endothelial to mesenchymal transition marker and fibroblast-specific protein 1 25, 26 were detected in cultured hPSC pericytes. It would be interesting in future studies to identify the developmental origin of hPSC pericytes on the basis of germ line-specific markers and cell tracing in developing hPSC.
We demonstrate here that transplantation of hPSC pericytes significantly attenuated critical limb ischemia. A physiological role of hPSC pericytes in various injury and regeneration models remains, however, to be further demonstrated. Currently, the endothelial and perivascular derivatives, which are coderived from a single source of hPSC, can be used by in vitro models for drug screening, biological studies of pericyte-endothelial interactions, and engineering of 3-dimensional vascular grafts. Importantly, given that our protocol allows efficient generation of pericytes from hIPSC, it can be applied for isolation of pericytic precursors from hIPSC with inherited genetic mutations for evaluation of a variety of pericyte degree of plasticity or dysfunctions. Considering the shortage in sources for uniform cultures of pericytes, the complex ontogeny of pericytes in animal experimental models, and the elusive origin of human pericytes, the use of developing hPSC as a human in vitro model for pericyte identification, isolation, and expansion can strongly contribute to studies of development and origin of pericytes and can be essential for improving differentiation protocols, generation of vascular constructs, disease modeling, and development of strategies in regenerative medicine.
